中小剂量利培酮治疗首发精神分裂症疗效与血药浓度的关系

目的：探讨中小剂量利培酮对精神分裂症的疗效和副反应及与血药浓度的关系。方法：42例接受小剂量利培酮（A组）患者，以中等剂量利培酮（B组，40例）为对照；利培酮治疗8周，以阳性和阴性症状量表（PANSS）评定疗效，以不良反应症状量表（TESS）评定不良反应。结果：A、B两组治疗前后自身对照有统计学意义（P〈0．05），两组间比较无统计学意义（P〉0．05）。A组生效时间比B组晚，A组的TESS总分显著低于B组。1周末9-羟利培酮（9-OH—RSP）与活性物（RSP＋9-OH—RSP）血浓度，B组均显著高于A组（P〈0．05）。结论：中小剂量利培酮对首发精神分裂症有确切疗效，9-羟利培酮血浓度、活性物血浓度均与疗效及不良反应关系密切。

Relationship of plasma risperidone concentration and the efficacy in treatment of first-episode schizophrenia after a middle or low dosage risperidone adminstration

AIM: To study the efficacy and side effects of both middle and low doses of risperidone in the treatment of first-episode schizophrenia, and to investigate the relationship between plasma concentration of RSP,9-OH-RSP and the efficacy or side effects occurred during RSP treatment. METHODS: Compared the patients treated with middle dosage of risperidone (groupB,40 cases)and the other 42 cases (groupA) that are treated with very low dosage of risperidone. RESULTS: Two groups were in statistical difference (P< 0.05 ) by itself. But there were no significant difference between group A and group B (P< 0.05 ). Group A took effect later than group B. Total scores of the treatment emergent symptom scale (TESS) were significantly lower in group A than in group B.The plasma concentration of 9-OH-RSP and the active moiety (RSP+9-OH-RSP) after one week's administration of risperidone were higher in group B than that in group A (P< 0.05 ). CONCLUSION: This assay suggested that low dosage of risperidone is effective, safe and beneficial in the treatment of first-episode schizophrenia.